WALTHAM, Mass., Oct. 13, 2025 – Ardelyx, Inc. (Nasdaq: ARDX) announced today the appointment of Sue Hohenleitner as its Chief Financial Officer, effective November 4, 2025. Hohenleitner brings more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development, most recently serving as Vice President and CFO of Johnson & Johnson Innovative Medicine North America.
"I am thrilled to welcome Sue to the Ardelyx leadership team," said Mike Raab, President and CEO. "Her proven ability to execute growth strategies and drive operational excellence will be instrumental as we expand our commercial success and pursue new opportunities for growth. Her leadership and financial discipline will help accelerate Ardelyx’s momentum, strengthen our foundation and position the company for long‑term success." Hohenleitner will assume the CFO role after the completion of Ardelyx’s third‑quarter 2025 financial reporting, with current Chief Financial and Operations Officer Justin Renz continuing in his role through the filing of the company’s Quarterly Report on Form 10‑Q.
"I am very excited to join Ardelyx at this important time in its evolution," Hohenleitner said. "With two first‑in‑class medicines helping patients and plans for expansion in the years ahead, I look forward to working with the team to shape strategic paths for long‑term growth and innovation for patients everywhere."
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.